REGEN-COV as the First Line of Defense—A Single-Centre Experience
Our study showed that in high-risk patients, with specific variants of SARS-CoV-2, the use of REGEN-COV was associated with a lower risk of hospitalization, and it was associated with better disease outcomes. One of the limitations of this study was the variant-specific effectiveness of REGEN-COV, which may limit generalizability.
Authors
- Sonja Golubović (ORCID: https://orcid.org/0000-0003-3716-698X)
- Nadica KOVACEVIC
- Vladimir Đurović (ORCID: https://orcid.org/0009-0008-0437-1200)
- Lada Petrović (ORCID: https://orcid.org/0000-0002-3942-6485)
- Slobodan Sajinovic
- Milica Popovic (ORCID: https://orcid.org/0000-0003-0999-3777)
- Tatjana Ilić
- Bojana Ljubicic
Institutions
- University of Novi Sad (RS)
- Klinički centar Vojvodine (RS)
- Kreativno Edukativni Centar (RS)
Publication Details
- Journal
- Life
- Published
- 2026-01-04
- DOI
- https://doi.org/10.3390/life16010074
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00